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Introduction
Clinical trials of ibrutinib have demonstrated consistent benefits and improve-
ments in overall survival (OS) and progression-free survival (PFS) among patients
with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and
relapsed or refractory mantle cell lymphoma (MCL), including those with high-risk
The first-in-class Bruton’s tyrosine kinase inhibitor ibrutinib hasproven clinical benefit in B-cell malignancies; however, atrial fibril-lation (AF) has been reported in 6-16% of ibrutinib patients. We
pooled data from 1505 chronic lymphocytic leukemia and mantle cell
lymphoma patients enrolled in four large, randomized, controlled studies
to characterize AF with ibrutinib and its management. AF incidence was
6.5% [95% Confidence Interval (CI): 4.8, 8.5] for ibrutinib at 16.6-
months versus 1.6% (95%CI: 0.8, 2.8) for comparator and 10.4%
(95%CI: 8.4, 12.9) at the 36-month follow up; estimated cumulative inci-
dence: 13.8% (95%CI: 11.2, 16.8). Ibrutinib treatment, prior history of
AF and age 65 years or over were independent risk factors for AF.
Multiple AF events were more common with ibrutinib (44.9%; compara-
tor, 16.7%) among patients with AF. Most (85.7%) patients with AF did
not discontinue ibrutinib, and more than half received common antico-
agulant/antiplatelet medications on study. Low-grade bleeds were more
frequent with ibrutinib, but serious bleeds were uncommon (ibrutinib,
2.9%; comparator, 2.0%). Although the AF rate among older non-trial
patients with comorbidities is likely underestimated by this dataset,
these results suggest that AF among clinical trial patients is generally
manageable without ibrutinib discontinuation (clinicaltrials.gov identifier:
01578707, 01722487, 01611090, 01646021).
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ABSTRACT
disease features.1-4 Ibrutinib therapy is generally well toler-
ated, but has been associated with atrial fibrillation (AF),
with an overall clinical trial incidence of 6-16%.1-6 In a
phase II study that enrolled 86 patients with CLL/SLL,
incidence of AF reached 16% in longer-term follow up.5 In
a meta-analysis,7 the pooled rate of AF was 3.3 [95%
Confidence Interval (CI): 2.5, 4.1] per 100 person-years in
ibrutinib-treated patients versus 0.84 (95%CI: 0.32, 1.6) per
100 person-years in non-ibrutinib-treated patients.
However, risk factors, natural history, and management
strategies of AF associated with ibrutinib treatment are
largely unknown. Because continuous treatment is
required to maintain benefit from single-agent ibrutinib
therapy, understanding a patient’s natural history and
optimizing AF management should improve the safe use
of ibrutinib in B-cell malignancies. Management of AF
typically relies on rate and/or rhythm control, depending
on underlying structural cardiovascular disease (CVD).8-10
Systemic thromboembolic events (specifically stroke)
are the most frequent major complication of AF, along
with other cardiovascular (CV) complications and
increased mortality.11,12 Anticoagulation, commonly with
vitamin K antagonists, reduces the risk of stroke by
approximately two-thirds, while increasing bleeding risks.
Thus, risk calculators (i.e. CHA2DS2-VASC) have been
developed to weigh benefits against risks of anticoagula-
tion in patients without an underlying malignancy.
Most patients with CLL/SLL and non-Hodgkin lym-
phomas are diagnosed at 65 years or over and have multi-
ple medical comorbidities.5,13,14 It has been reported that
6% of patients aged 65 years or over and diagnosed with
CLL/SLL had AF at baseline (higher than the 1.0-1.8% of
an age-matched general population), and 6% more devel-
oped AF over a 5-year treatment period,13-15 suggesting that
patients with CLL/SLL may have a higher risk of develop-
ing AF than the normal population.
Data regarding management of AF in ibrutinib-treated
patients are limited, and the association between ibrutinib
therapy and increased rates of bleeding needs to be con-
sidered in the context of AF management in these
patients. To further characterize ibrutinib-associated AF
and describe management thereof, we report here a
pooled analysis of all cases of AF across four randomized
controlled trials (RCTs).
Methods
Study populations from initial data reports of the four RCTs
[PCYC-1112 (RESONATE, clinicaltrials.gov identifier: 01578707),
PCYC-1115 (RESONATE-2, clinicaltrials.gov identifier: 01722487),
CLL3001 (HELIOS, clinicaltrials.gov identifier: 01611090), and
MCL3001 (RAY, clinicaltrials.gov identifier: 01646021)] were pooled,
including patients randomized to receive ibrutinib [alone or with
bendamustine plus rituximab (BR)] and patients receiving com-
parator therapy (ofatumumab, chlorambucil, placebo plus BR, or
temsirolimus). The studies were approved by the institutional
review board or independent ethics committee at each institution.
Data from the initial study reports were used for the detailed
pooled analysis. Limited data on incidence of AF were available in
the extended follow-up period and were included for patients ran-
domized to ibrutinib. Patients were subject to similar eligibility
criteria; specifically, patients requiring vitamin K antagonists, such
as warfarin, or strong CYP3A4/5 inhibitors were excluded,
although other anticoagulants and antiplatelet agents were permit-
ted. Patients were censored at crossover. Patients were excluded if
they had uncontrolled or clinically significant CVD, including
uncontrolled arrhythmia or class III or IV congestive heart failure
or a history of myocardial infarction, unstable angina, or acute
coronary syndrome within six months prior to randomization.
Complete study methodologies are detailed elsewhere (Online
Supplementary Appendix 1).1-4
The incidences of AF and atrial flutter events were referred to
collectively as AF. All treatment-emergent AF events (defined as
events occurring after first dose of study drug until 30 days after
last dose) are reported. CV events captured using Standardised
Medical Dictionary for Regulatory Activities (MedDRA) Queries
(SMQ) were grouped into five CVD categories: arrhythmia, con-
gestive heart failure, ischemic heart disease, hypertension, and
ischemic CNS vascular conditions (Online Supplementary Appendix
2). Bleeding events listed were captured using SMQ.
CHA2DS2-VASc scores estimating risk of stroke in patients with
AF were evaluated using patients’ characteristics at baseline. Cox
regression models were used to perform univariate and multivari-
ate analyses of risk factors for developing AF. These analyses eval-
uated age increase, gender (male), AF risk increase (prior history of
AF/flutter), increase in body mass index, Rai stage and prior histo-
ry of AF/abnormal heart rhythm, coronary artery disease, dia-
betes, hyperlipidemia, hypertension, and valvular heart disease.13
The univariate model included each single factor plus treatment
group. Cumulative incidence of AF was estimated in a Cox regres-
sion model accounting for deaths and disease progression without
prior AF as competing risk events.5,16 The AF risk score for each
CLL patient with no prior history of AF was computed using the
Shanafelt predictive model.13
Results
Patients’ characteristics and incidence of AF
In total, 1505 patients were included, with 756 random-
ized to ibrutinib (alone or with BR) and 749 to comparator
(Table 1). One hundred thirty-nine patients had previously
treated MCL and the remainder had newly diagnosed or
previously treated CLL. At the time of the initial study
reports, the median follow up in the pooled analysis was
16.6 months; median duration of exposure was 13.3
months for the ibrutinib group and 5.8 months for the
comparator (Online Supplementary Table S1). With a medi-
an follow up of 16.6 months, 6.5% (95%CI: 4.8, 8.5) of
patients receiving ibrutinib and 1.6% (95%CI: 0.8, 2.8)
receiving the comparator [relative risk 4.1 (95%CI: 2.2,
7.5)] reported AF while on treatment (Figure 1).  Most AF
events developed de novo in patients without a history of
AF. The incidence of AF was 7.0% (95%CI: 5.1, 9.3) in
CLL patients and 4.3% (95%CI: 1.6, 9.2) in MCL patients
treated with ibrutinib. Patients treated with ibrutinib com-
bination therapy (HELIOS study) had a 7.7% (95%CI: 4.9,
11.4) incidence of AF, compared with 5.8% (95%CI: 3.8,
8.3) in ibrutinib monotherapy patients. The exposure-
adjusted incidence rates of AF per 100 patient-months
were  0.503 for the ibrutinib group and  0.199 for the com-
parator. The estimated cumulative incidence of AF was
higher in patients treated with ibrutinib versus compara-
tors [7.4% (95%CI: 5.6, 9.6) vs. 1.9% (95%CI:1.0, 3.4)]
(Figure 2A and B). Median age of patients developing AF
was 71 years for both groups, which is older than the
overall median age of 67 years. History of prior AF/abnor-
mal heart rhythm was more common in patients who had
AF on study (ibrutinib, 26.5%; comparator, 25.0%) than in
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patients who did not (ibrutinib, 10.6%; comparator,
10.4%). Patients with a history of hypertension were
more likely to develop AF than those without [31 of 328
(9.5%) vs. 18 of 428 (4.2%)] in the ibrutinib group. The
majority of patients with prior hypertension did not
develop clinically evident AF on ibrutinib (ibrutinib,
90.5%; comparator, 96.9%) during the observation peri-
od. In patients without a history of hypertension, 38
developed de novo hypertension; only one patient devel-
oped de novo hypertension and AF.
Longer-term follow up in patients randomized to ibruti-
nib provided an additional 8467 patient-months for analy-
sis. During this period, 29 additional patients experienced
AF. Newly reported cases of AF occurred at a continuous
low rate over time. With extended follow up, 78 ibrutinib-
treated patients [10.4% (95%CI: 8.4, 12.9)] experienced
AF. Estimated cumulative incidence rate of AF at 36
months was 13.8% (95%CI: 11.2, 16.8) (Figure 2C). After
adjusting for competing risks of progressive disease and
death, estimated cumulative incidence rate of AF was
11.2% (95%CI: 9.0, 13.8) (Figure 2D).
Clinical features of treatment-emergent AF
In the first six months, 5.3% of ibrutinib patients devel-
oped AF with a continued low rate over time. The median
time to onset of AF was 2.8 months (range 0.3-17.5) for
the ibrutinib group and 2.0 months (range 0.6-18.9) for the
comparator, with a median follow up of 16.6 months. In 2
patients in the ibrutinib group and 4 in the comparator, an
AF event occurred after the patient had permanently dis-
continued study drug (within 30 days) for other reasons.
Overall, median duration of AF episodes was three days
for both groups; however, the range varied widely. The
mean (SD) duration of AF episodes was 12.6 (29.5) days
for the ibrutinib group and 5.1 (5.5) days for comparator.
The majority of patients experiencing AF had only one
episode [27 of 49 (55.1%) for ibrutinib; 10 of 12 (83.3%)
for comparator] (Online Supplementary Table S2); 22
patients (44.9%) in the ibrutinib group had multiple
episodes and 2 patients (16.7%) in the comparator had
two episodes (Online Supplementary Tables S2 and S3).
Among patients who had two or more AF episodes in the
ibrutinib group, the median time between events was 1.1
months.
Common Toxicity Criteria grade 1 or 2 AF occurred in
27 (3.6%) patients in the ibrutinib group and 8 (1.1%)
patients in the comparator group, accounting for more
than half of the AF events that occurred in either group
(Online Supplementary Appendix 3). AF events leading to
hospitalization (including grade 3 and 4 events) were
reported as serious adverse events (SAEs) in 23 (3.7%)
patients receiving ibrutinib and 6 (1.0%) receiving com-
parator. Among these SAEs, 17 patients in the ibrutinib
group and 3 patients in the comparator group reported
grade 3 events. Only one grade 4 event was reported,
which was in the ibrutinib group. No deaths were attrib-
uted to AF in either group. 
With extended follow up, the median time to onset of
AF in patients randomized to ibrutinib was 5.7 (range 0.3-
40.2) months. Of the 78 patients with AF, almost two-
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Table 1. Baseline demographic and clinical characteristics of patients in the pooled analysis.
Ibrutinib Comparator
All patients Patients with AF All patients Patients with AF
(n=756) (n=49) (n=749) (n=12)
Median age, years (range) 67.0 (30-89) 71.0 (59-84) 67.0 (34-90) 71.0 (58-88)
<65, n (%) 274 (36.2) 9 (18.4) 288 (38.5) 1 (8.3)
65-75, n (%) 324 (42.9) 26 (53.1) 331 (44.2) 8 (66.7)
>75, n (%) 158 (20.9) 14 (28.6) 130 (17.4) 3 (25.0)
Male, n (%) 508 (67.2) 33 (67.3) 506 (67.6) 9 (75.0)
Ethnicity (White), n (%) 670 (88.6) 47 (95.9) 686 (91.6) 12 (100)
BMI, n (%)a
≤18 6 (0.8) 0 6 (0.8) 0
>18-24.9 284 (37.6) 17 (34.7) 256 (34.2) 2 (16.7)
25-29.9 276 (36.5) 21 (42.9) 288 (38.5) 3 (25.0)
≥30 166 (22.0) 9 (18.4) 166 (22.2) 7 (58.3)
Anticoagulant at baseline, n (%) 41 (5.4) 4 (8.2) 41 (5.5) 2 (16.7)
Antiplatelet at baseline, n (%) 131 (17.3) 17 (34.7) 148 (19.8) 2 (16.7)
Prior history for patients, n (%)
AF/abnormal heart rhythm 88 (11.6) 13 (26.5) 80 (10.7) 3 (25.0)
Coronary artery disease 41 (5.4) 3 (6.1) 36 (4.8) 0
Diabetes 98 (13.0) 7 (14.3) 122 (16.3) 5 (41.7)
Hyperlipidemia 49 (6.5) 8 (16.3) 48 (6.4) 1 (8.3)
Hypertension 328 (43.4) 31 (63.3) 327 (43.7) 10 (83.3)
Infection 289 (38.2) 26 (53.1) 300 (40.1) 5 (41.7)
AF: atrial fibrillation; n: number; BMI: body mass index. aTwenty-four patients with ibrutinib and 33 with placebo had missing BMI at baseline.
thirds [49 (62.8%)] had only one episode of AF and more
than half [43 (55.1%)] had AF events of grade 2 or lower
(Online Supplementary Table S4).
Predictors of AF in trial patients
Univariate analyses identified prior history of AF, ibruti-
nib therapy, age over 65 years, hypertension, and hyper-
lipidemia as significant risk factors for developing AF.
Multivariate analyses showed prior history of AF, ibruti-
nib therapy, and age over 65 years as independent predic-
tors of AF (Figure 3). The influence of prior coronary artery
disease, valvular heart disease, and diabetes were also
evaluated and not identified as significant risk factors for
developing AF while on ibrutinib.
In CLL patients without a history of AF who were treat-
ed with ibrutinib, the incidence and risk of de novo AF
increased with Shanafelt risk score category (Table 2 and
Online Supplementary Figure S1). Estimated 5-year de novo
AF rates were 0.4% in category 0-1, 2.8% in category 2-3,
7.6% in category 4, and 17.9% in category ≥5.
Management of study therapy concurrent with 
AF events
Twenty-four of 49 patients with AF in the ibrutinib
(49.0%) and 4 of 12 in the comparator (33.3%) group were
managed without any interruption or modification of
study drug. Patients who required dose modification or
interruption were slightly older; all other baseline demo-
graphic and clinical characteristics were similar between
the two groups (Online Supplementary Table S5).
No patient in either group had a dose reduction attrib-
uted to AF; however, a similar proportion in each group
had dose interruptions due to AF [16 of 49 (32.7%) for
ibrutinib; 4 of 12 (33.3%) for comparator]. The median
duration of interruption was 11 days for ibrutinib and 17
days for comparator. With the caveat of small numbers,
there was no statistical difference between the 18-month
PFS rate in 6 patients with AF who had ibrutinib dose
interruption for seven days or more versus those with dose
interruption for fewer than seven days [66.7% (95%CI:
19.5, 90.4) vs. 71.4% (95%CI: 54.0, 83.2)]. Seven of 49
(14.3%) patients in the ibrutinib group and no patients in
the comparator group discontinued study treatment due
to AF. Approximately one-half of patients with multiple
AF events had dose interruptions (Online Supplementary
Figure S2), and 5 of 22 (22.7%) discontinued. Plots of AF
events, dose interruptions, and concomitant therapy for
individual patients with AF are found in the Online
Supplementary Figure S2. Of ibrutinib patients with AF and
extended follow up, approximately half [41 of 78 (52.6%)]
were managed without dose reduction or interruption of
study treatment (Online Supplementary Table S4).
Medical management of AF
Atrial fibrillation was primarily managed with treat-
ment commonly used for rate and rhythm control, with
the most frequently used agents digoxin [11 of 49
(22.4%)], bisoprolol [10 of 49 (20.4%)], and amiodarone [8
of 49 (16.3%)] in the ibrutinib group, and amiodarone [4
of 12 (33.3%)] and diltiazem [3 of 12 (25.0%)] in the com-
parator group (Online Supplementary Table S6A). In the
ibrutinib group, 2 patients were managed using cardiover-
sion and one had a pacemaker inserted due to concomi-
tant bradycardia. Patients did not have serial electrocar-
diographic monitoring to evaluate return to normal sinus
rhythm; however, 36 of 49 patients receiving ibrutinib
(73.5%) and 9 of 12 receiving comparator (75.0%) had
their AF events reported as recovered or resolved.
More than one-third [17 of 49 (34.7%)] of ibrutinib
patients who had an AF event on study were taking
antiplatelet medications at study entry, and 4 (8.2%) were
taking an anticoagulant. In the comparator group, 2
patients each were on antiplatelet and anticoagulant med-
ications (Table 1). Many patients who experienced AF
received concomitant anticoagulant and/or antiplatelet
medication; the most commonly used antiplatelet agent
was aspirin, and the most commonly used anticoagulant
was low-molecular-weight heparin (Online Supplementary
Table S6A and B). Among ibrutinib-treated patients who
received anticoagulant/antiplatelet medications at any
Pooled AF analysis in ibrutinib studies
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Figure 1. Onset of first atrial fibrillation event by
treatment.
time on study, median treatment duration was longest for
aspirin and novel oral anticoagulants (Online Supplementary
Table S6A and B and Online Supplementary Figure S2).
Patients with AF tended to have higher CHA2DS2-VASc
scores regardless of study treatment, with 35 of 49 ibruti-
nib patients and 10 of 12 comparator patients having
scores ≥2 (Online Supplementary Table S7). All 35 ibrutinib
patients received anticoagulation: 23 (65.7%) received an
anticoagulant alone and 12 (34.3%) received both antico-
agulant and antiplatelet medications. All 10 patients in the
comparator group received an anticoagulant and 20.0% of
those also received an antiplatelet agent.
Bleeding events with the use of anticoagulant and
antiplatelet medications
Overall, 38.8% (293 of 756) of patients in the ibrutinib
group and 17.2% (129 of 749) of patients in the compara-
tor experienced a bleeding event; most in each group were
grade 1 or 2 (91.5% and 88.3%, respectively). Bleeding
occurred irrespective of whether patients experienced AF
(Table 3). Of the patients with AF, 25 of 49 (51.0%) in the
ibrutinib group had bleeding events; timing of the bleed-
ing events relative to onset of AF was not evaluated.
Bleeding events were grade 1 or 2 in severity in all patients
in the ibrutinib group (Online Supplementary Figure S3). In
J.R. Brown et al.
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Table 3. Rates of bleeding in ibrutinib and comparator patient groups in terms of the presence of atrial fibrillation (AF)  and use of antiplatelet
and/or anticoagulant agents.
Ibrutinib Comparator
(n=756) (n=749)
Patients Patients All Patients Patients All 
with AF without AF patients with AF without AF patients
N. (%) (n=49) (n=707) (n=756) (n=12) (n=737) (n=749)
Any bleeding event 25/49 268/707 293/756 2/12 127/737 129/749
(51.0) (37.9) (38.8) (16.7) (17.2) (17.2)
Grade 1/2 events 24/49 244/707 268/756 1/12 113/737 114/749
(49.0) (34.5) (35.4) (8.3) (15.3) (15.2)
Grade 3/4 events 1/49 (2.0) 21/707 (3.0) 22/756 (2.9) 1/12 (8.3) 14/737 (1.9) 15/749 (2.0)
Antiplatelet/anticoagulant use in patients with n=25 n=268 n=293 n=2 n=127 n=129   
bleeding event of any  gradea
Anticoagulant medication 13/25 27/268 40/293 0 18/127 18/129
(52.0) (10.1) (13.7) (14.2) (14.0)
Antiplatelet medication 6/25 37/268 43/293 0 19/127 19/129
(24.0) (13.8) (14.7) (15.0) (14.7)
Anticoagulant and 4/25 3/268 7/293 0 3/127 3/129
antiplatelet medications given (16.0) (1.1) (2.4) (2.4) (2.3)   
in combination
No anticoagulant or 10/25 210/268 220/293 2/2 93/127 95/129
antiplatelet medication (40.0) (78.4) (75.1) (100) (73.2) (73.6)
N, n: number.  aBleeding events are counted if they are between seven days prior and one day post-administration of anticoagulant/antiplatelet.
Table 2. Incidence of de novo atrial fibrillation (AF) by Shanafelt risk score category13 in chronic lymphocytic leukemia  patients with no history
of AF treated with ibrutinib.
Risk score N. patients (%) N. patients HR Estimated 5-year Estimated 5-year 
category n=588 with AF (%) (95% CI) AF ratea AF rate
% (95%CI) % (95%CI)13,b,c
0-1 282 (48.0) 10 (3.5) Ref 0.40 1.8
(0.1-2.8) (0.8-2.8)
2-3 209 (35.5) 16 (7.7) 2.294 2.8 4.1
(1.016-5.183) (1.2-6.5) (2.5-5.6)
4 71 (12.1) 6 (8.5) 2.997 7.6 8.0
(1.089-8.250) (2.9-19.2) (4.8-11.0)
≥5 26 (4.4) 4 (15.4) 3.289 17.9 17.2
(0.868-12.467) (6.8-42.1) (10.3-23.5)
HR: Hazards Ratio; CI: Confidence Interval; N, n: number; Ref: reference. aEstimated by Cox regression model for time to acquired AF from diagnosis. Median follow up on study
for the patients was 15.4 months. Median follow-up time from diagnosis was 89.1 months. bMedian follow up was 7.3 years. cRisk score was the sum of the risk values across each
factor independently associated with AF,  older age (65-74: 2, ≥75+: 3), male gender (1), valvular heart disease (2), and hypertension (1). 
the ibrutinib group, 10 of 25 (40.0%) patients had not
received anticoagulant/antiplatelet medication. Nine
(36.0%) patients were receiving a single
anticoagulant/antiplatelet medication at the time of the
bleeding event (aspirin, n=1; novel oral anticoagulants,
n=5; low-molecular-weight heparin, n=3), and 6 (24%)
were receiving at least two medications (2 of whom
received three). All 35 patients with CHA2D22-VASc
scores ≥2 who developed AF on ibrutinib received antico-
agulant/antiplatelet medication. 
During the study, 12 (34.3%) of these patients had a
grade 1 or 2 bleeding event, 7 of whom were on a single
anticoagulant/antiplatelet medication and 5 of whom
were on two or more medications.
Three bleeding events resulted in death, all in the ibruti-
nib group (ruptured abdominal aortic aneurism, subdural
hematoma, post-procedural hemorrhage); one patient was
on aspirin at the time of the fatal bleed, the other 2
patients had not received concomitant
anticoagulants/antiplatelets, while none of the patients
had AF while on treatment (Online Supplementary Table
S8).
Clinical sequelae of AF
Cardiovascular disease clinical sequelae were captured
using MedDRA SMQ and grouped into five CVD cate-
gories: arrhythmia, congestive heart failure, ischemic
heart disease, hypertension, and ischemic CNS vascular
conditions (Online Supplementary Appendixn 2). Among
patients who had a single AF episode, these CVD clinical
sequelae were seen with similar frequency in both groups:
5 of 27 (18.5%) of patients in the ibrutinib group com-
pared with 2 of 10 (20.0%) patients in the comparator
(Online Supplementary Table S9). Thirteen patients on ibru-
tinib who had multiple AF episodes, and both patients on
comparator, developed clinical CVD sequelae; 9 (69.2%)
and 2 (100%) patients, respectively, had a history of one
of these conditions. One comparator-treated patient with
an AF event had an ischemic CNS vascular condition
within the observation time; no ibrutinib-treated patients
had an ischemic CNS vascular condition.
Given that clinical complications of AF can occur in the
absence of clinically symptomatic AF, incidences of car-
diovascular events (as defined above) were also evaluat-
ed in the full cohort. Hypertension was the only group
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Figure 2. Cumulative incidence (95% CI) of atrial fibrillation with ibrutinib. (A) unadjusted for competing risks (death and progressive disease) and (B) adjusted. With
extended follow up: unadjusted (C) and adjusted (D).
A
C
B
D
term that occurred on study at a significantly higher rate
in the ibrutinib group compared with the comparator
(Table 4). Furthermore, CLL patients experiencing AF on
ibrutinib had similar PFS duration as patients who did
not (Figure 4).
Discussion
Ibrutinib has shown a highly favorable benefit-risk ratio
for patients with CLL/SLL and relapsed or refractory
MCL, albeit with certain side effects including AF. To date,
the risk factors, natural history, therapeutic management,
and outcomes of ibrutinib-related AF have not been well
characterized. In this pooled analysis of four RCTs, with a
median follow up of 16.6 months, the incidence of AF in
patients treated with ibrutinib was 6.5% (95%CI: 4.8,
8.5%). The incidence of AF was 10.4% (95%CI: 8.4, 12.9)
with additional follow up, which is relatively consistent
with prior clinical studies and independent reports.5,13,17-20
The incidence of AF was highest in the first six months,
and then continued at a low rate. Multivariate analysis
showed that use of ibrutinib, prior history of AF, and age
over 65 years were associated with a higher risk of AF.
Older patients, in general, have a higher propensity for
CVD including AF, so it is not surprising that the patients
developing AF in this pooled analysis were older than the
overall study population. In addition, although history of
AF was a predictor of AF in this pooled analysis, we noted
that 85.2% of patients with a history of AF did not have a
recurrence while being treated with ibrutinib at a median
follow up of 16.6 months. However, the small number of
patients with AF and the exclusion of patients with signif-
icant cardiac disease from the clinical trials may limit the
interpretation of the findings in other patient populations.
Given the rate of AF is highest in the first six months of
ibrutinib therapy and may be higher in older, non-trial
populations, patients should be carefully monitored for
signs of AF, particularly if they are older or have a pre-
existing history.
In a separate analysis investigating only those patients
on ibrutinib without a prior history of AF, we investigated
the utility of the Shanafelt risk score in estimating the like-
lihood of developing AF among our CLL study population
on ibrutinib, using a similar methodology as the original
report.13 In the Shanafelt predictive model, older age, male
gender, valvular heart disease, and hypertension were
identified as risk factors independently associated with de
novo AF at the time of CLL diagnosis.13 We observed a sim-
ilar increased risk of de novo AF among patients with high-
er score categories, which may be useful for counseling
patients. The estimated 5-year AF rates were similar to
those observed in the original report.13
Current recommendations for management of AF in
patients on ibrutinib indicate that therapy should be inter-
rupted for any new onset or worsening grade ≥3 non-
hematologic toxicity, including AF. Once symptoms have
resolved to grade 1 or baseline, treatment may be reiniti-
ated at the starting dose. For patients who develop AF,
physicians should follow the appropriate guidelines for
clinical management of AF. In this pooled analysis, the
approach to AF management was heterogeneous and
included practices in accordance with the ibrutinib proto-
col recommendations and prescribing information as well
as CV standard of care for AF.21,22 Approximately half of
patients developing AF on ibrutinib were able to be man-
aged without dose interruption or modificiation. In a
recent report by Thompson et al., patients with CLL who
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Figure 3. Significant factors for devel-
opment of atrial fibrillation using uni-
variate and multivariate Cox regres-
sion. HR: Hazards Ratio; CI:
Confidence Interval.
had ibrutinib interrupted at the the onset of AF had an
inferior PFS compared with that seen in patients who con-
tinued ibrutinib or had dose reductions.23
In this analysis, interrupting ibrutinib therapy for seven
days or more in the context of AF did not appear to signif-
icantly impact 18-month PFS; given the limited sample
size, however, these findings should be interpreted with
caution. The majority of the patients did not discontinue
ibrutinib due to AF so limited data were available on
patients receiving an alternative therapy due to AF in our
study. Among 7 patients who discontinued ibrutinib, one
patient received subsequent chemoimunotherapy with
BR. However, there are a number of  agents in the CLL
landscape that provide alternative options for CLL
patients who may need to discontinue ibrutinib treatment
due to AF, including novel agents like idelalisib and vene-
toclax.  A few reports have been published on patient out-
comes after ibrutinib discontinuation due to AEs, and sug-
gest that outcomes are better than those seen in the set-
ting of disease progression.24
The approach to medical management of AF in patients
receiving ibrutinib should take into account the potential
risk of pharmacokinetic interactions with commonly used
anticoagulant/antiplatelet medications. US prescribing
information for ibrutinib currently recommends a dose
reduction to 140 mg daily for co-administration with
moderate CYP3A/4 inhibitors.21,22 At the time the studies
in this pooled analysis were conducted, however, dose
interruption or modification was at the physician’s discre-
tion, and many patients continued on full-dose ibrutinib
while receiving moderate CYP3A/4 inhibitors to manage
AF, specifically amiodarone and diltiazem. It was beyond
the scope of the current analysis to determine whether
increased toxicity resulted from this approach; however,
current practice and prudence would dictate avoidance of
CYP3A/4 inhibitors if possible or dose reduction of ibruti-
nib consistent with the prescribing information.21,22
In vitro studies suggest that ibrutinib induces platelet
aggregation defects due to the inhibition of Bruton’s tyro-
sine kinase and TEC in the glycoprotein VI collagen-acti-
vated pathway,25,26 and therefore concomitant use of anti-
coagulants or aspirin with ibrutinib could enhance bleed-
ing risk. In the current analysis, serious bleeding events
occurred in 2.9% of patients treated with ibrutinib overall
and in 2.0% of patients with AF. Due to the heteroge-
neous approach to AF management, it was difficult to
characterize the impact of specific medication combina-
tions on the risk of bleeding; however, the very low inci-
dence of grade ≥3 bleeding events, even among patients
receiving more than one anticoagulant/antiplatelet agent,
is reassuring. These results, however, are in contrast to a
recent report of real-world experience with 56 patients
who developed AF on ibrutinib, in whom a 14% rate of
major bleeding was seen.6 These results suggest that more
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Figure 4. Progression-free survival in patients with
and without atrial fibrillation (AF). 
Table 4. Cardiovascular (CV) events occurring while on therapy listed by MedDRA SMQ grouping.a
Higher level term, n (%) Ibrutinib Comparator P
(n=756) (n=749)
Hypertension 71 (9.4) 26 (3.5) <0.0001
Congestive heart failure 151 (20.0) 163 (21.8) 0.7118
Ischemic cardiac disease 17 (2.2) 17 (2.3) 0.4802
Ischemic CNS vascular conditions 10 (1.3) 6 (0.8) 0.3044
Arrhythmia 55 (7.3) 46 (6.1) 0.1148
SMQ: Standardised MedDRA Queries; n: number; CNS: central nervous system. aCV events captured using MedDRA SMQ were grouped into five cardiovascular disease cate-
gories (Online Supplementary Appendix 2). 
data are needed on the specific risk factors for major
bleeds in ibrutinib-treated patients, and until those are
available, additional caution and monitoring are warrant-
ed in clinical practice, particularly for older patients with
comorbidities who are likely to have a higher bleeding
risk.6 Notably, in this analysis, no thromboembolic events
were observed among ibrutinib-treated patients develop-
ing AF. It will be of interest for future studies to determine
whether ibrutinib use itself has sufficient antiplatelet
activity to confer some of the benefits of aspirin or other
antiplatelet agents.
In this pooled analysis of relatively young and healthy
clinical trial subjects, we did not find an increased rate of
congestive heart failure, ischemic cardiac disease, stroke,
or other arrhythmias among patients with AF in the ibru-
tinib group relative to the comparator. This finding should
be interpreted with caution given the small sample size
and limited follow up; however, it is notable given that
patients with AF generally had higher rates of comorbidi-
ties like hypertension and hyperlipidemia at study entry.
When we evaluated the study population as a whole
(regardless of the presence of symptomatic AF), we noted
an increase in the incidence of de novo and recurrent or
ongoing hypertension in patients treated with ibrutinib.
Patients with a history of hypertension were more likely
to develop AF; however, in patients without a history of
hypertension, 38 of 428 patients developed de novo hyper-
tension but only one patient developed de novo hyperten-
sion and AF, suggesting that at least so far, these events are
not highly correlated. Ibrutinib therapy has been associat-
ed with hypertension in clinical trials, making it difficult to
discern if the signal we saw was a direct treatment effect
or clinical sequelae related to subclinical AF in a subset of
patients.
This analysis has inherent limitations, particularly in its
post hoc assessment of completed studies, which focused
primarily on oncological rather than CV outcomes. Patient
numbers in certain subgroups were low, despite having
access to data from four large RCTs, and the inclusion of
patients with MCL who received a different dose of ibru-
tinib and have different disease biology, as well as the
inclusion of patients treated with both ibrutinib alone or
in combination with BR, may impact on the interpretation
of the findings. The method of capturing AEs and con-
comitant medications limited our ability to evaluate dose
intensity, sequencing of anticoagulation in patients with
AF, and the temporal relationship between AF and bleed-
ing events. Furthermore, due to study exclusion criteria
related to certain serious comorbidities, patients on the
clinical trials were undoubtedly healthier than most treat-
ed in general practice. Given these limitations, this study
may underestimate the incidence of AF among older
patients treated outside a clinical trial setting with ibruti-
nib. A recently published retrospective study of CLL
patients treated at several cancer centers found that AF
persisted in 62% of 56 ibrutinib-treated patients despite
AF-directed therapy.6 Three episodes of cardiac failure,
one stroke, and major bleeding events in 14% of patients
were observed in that study.6 Algorithm-based guidelines
have been proposed to manage ibrutinib-associated AF
but have not yet been validated.27 Additional larger
datasets, perhaps population-based, will be required to
determine representative rates of AF with ibrutinib in dif-
ferent patient groups, to better characterize the incidence
of AF-related complications, and to evaluate the value of
proposed guidelines outside of a clinical trial setting.
Prudence dictates that clinicians consider the benefit-
risk profile of ibrutinib therapy in patients with a history
of AF or other predisposing risk factors. Results of this
pooled analysis of more than 1500 patients in four RCTs
suggest that, with appropriate vigilance and monitoring,
the majority of patients with known risk factors for AF
can be safely treated with ibrutinib.  Alternative treatment
options are available for those who discontinued ibrutinib
due to AF. However, most patients who develop AF on
treatment will not require treatment discontinuation and
many can be managed safely with commonly used antico-
agulant/antiplatelet medications. Prospective clinical stud-
ies focusing on detailed evaluation of the cardiac effects of
ibrutinib are warranted to further elucidate the potential
mechanisms of AF.28,29
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